These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17542153)

  • 1. Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent.
    Murakami E; Bao H; Basavapathruni A; Bailey CM; Du J; Steuer HM; Niu C; Whitaker T; Anderson KS; Otto MJ; Furman PA
    Antivir Chem Chemother; 2007; 18(2):83-92. PubMed ID: 17542153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism.
    Chu CK; Yadav V; Chong YH; Schinazi RF
    J Med Chem; 2005 Jun; 48(12):3949-52. PubMed ID: 15943470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
    AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
    Lennerstrand J; Chu CK; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.
    Álvarez M; Nevot M; Mendieta J; Martínez MA; Menéndez-Arias L
    J Biol Chem; 2018 Feb; 293(7):2247-2259. PubMed ID: 29275329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
    Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
    Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
    Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.
    Odriozola L; Cruchaga C; Andréola M; Dollé V; Nguyen CH; Tarrago-Litvak L; Pérez-Mediavilla A; Martínez-Irujo JJ
    J Biol Chem; 2003 Oct; 278(43):42710-6. PubMed ID: 12917424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
    Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
    J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
    Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.
    Matamoros T; Nevot M; Martínez MA; Menéndez-Arias L
    J Biol Chem; 2009 Nov; 284(47):32792-802. PubMed ID: 19801659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
    Goldschmidt V; Marquet R
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1687-705. PubMed ID: 15183338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
    Descamps D; Damond F; Matheron S; Collin G; Campa P; Delarue S; Pueyo S; Chêne G; Brun-Vézinet F;
    J Med Virol; 2004 Oct; 74(2):197-201. PubMed ID: 15332266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants.
    Boyer PL; Julias JG; Ambrose Z; Siddiqui MA; Marquez VE; Hughes SH
    J Mol Biol; 2007 Aug; 371(4):873-82. PubMed ID: 17597154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.